UNICANCER

The ASTER 70 phase III trial involving 1,089 patients aged 70 and older with high-risk ER+HER2- breast cancer found no significant overall survival benefit from adding chemotherapy to hormone therapy.

• Natera has enrolled the first patients in the HEROES phase II clinical trial, investigating the potential to safely discontinue anti-HER2 therapy in metastatic breast cancer patients with no detectable circulating tumor DNA. • The trial will use Natera's Signatera test to identify patients who may safely stop maintenance therapy, potentially freeing them from lifelong treatment regimens that can be costly and cause adverse effects. • Approximately 170 patients across 35 French sites will participate in the study, which could fundamentally change treatment approaches for the 15-20% of breast cancer patients with HER2-positive tumors.

Greenwich LifeSciences broadens its Phase III FLAMINGO-01 trial for GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence, by adding new clinical sites in the U.S. and Europe.

The HypoG-01 trial demonstrates that a 3-week hypofractionated radiotherapy regimen is equivalent to a 5-week normofractionated regimen for locoregional breast cancer.